First-pass extracted concept

TDP-43 pathology in Alzheimer's disease

Candidate: concept label1 source documents4 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

Title: TDP-43 Pathology in Alzheimer’s Disease

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2021Molecular NeurodegenerationDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1clinical significance summarysupports2021Source 1DOI PubMed

Upstream cited studies summarized for this review indicate that TDP-43 burden and distribution in pathologic Alzheimer's disease are associated with worse cognitive impairment and medial temporal atrophy.

Quoted textsource-backed

Large clinicopathologic study showing TDP-43 burden/distribution relates to worse cognitive impairment and medial temporal atrophy in pathologic AD, directly supporting the review’s clinical significance claims.

Claim 2disease framework contextsupports2021Source 1DOI PubMed

LATE and LATE-NC provide an important framework for interpreting limbic-predominant TDP-43 pathology in aging and Alzheimer's disease.

Quoted textsource-backed

The LATE/LATE-NC consensus framework contextualizes limbic-predominant TDP-43 pathology in aging and AD.

Claim 3review scopesupports2021Source 1DOI PubMed

The review focuses on TDP-43 pathology in Alzheimer's disease.

Quoted textsource-backed

TDP-43 Pathology in Alzheimer’s Disease

Claim 4staging summarysupports2021Source 1DOI PubMed

The supplied citation scaffold indicates that Alzheimer's disease-associated TDP-43 pathology has been described with a staged topographic progression.

Quoted textsource-backed

Foundational AD-specific staging paper defining a five-stage topographic progression of TDP-43 pathology, with regional sampling guidance and correlations to cognition and medial temporal atrophy.